HomeInsightsMarket Capitalization

Market Capitalization of Glenmark Pharmaceuticals Ltd

Market Capitalization of Glenmark Pharmaceuticals Ltd

stocks purchased

₹ 1.3 Cr

Volume Transacted

(Dec 26, 2024)

stocks purchased

8.6 K

Stocks Traded

(Dec 26, 2024)

Last Updated on: Dec 26, 2024

Image

Glenmark Pharmaceuticals Ltd

NSE: GLENMARK

Market Cap

₹ 43348.33 crore

Last updated on: Dec 24, 2024

Key Highlights

  • The Market Cap of Glenmark Pharmaceuticals Ltd is ₹ 43348 crore as of 24 Dec 24 .
  • The Market Cap of Glenmark Pharmaceuticals Ltd changed from ₹ 18215 crore on March 2019 to ₹ 27019 crore on March 2024 . This represents a CAGR of 6.79% over 6 years.
  • The Latest Trading Price of Glenmark Pharmaceuticals Ltd is ₹ 1526 as of 26 Dec 14:22 .
  • The dividend payouts of Glenmark Pharmaceuticals Ltd changed from ₹ 2 to ₹ 2.5 over 6 quarters. This represents a CAGR of 16.04% .

Historical Market Cap of Glenmark Pharmaceuticals Ltd

No data available

* All values are in crore

Company Fundamentals for Glenmark Pharmaceuticals Ltd

No data available

Image

Glenmark Pharmaceuticals Ltd

NSE: GLENMARK

Share Price

₹ 1526.85

-9.30 (-0.61%)

stock direction

Last updated on: Dec 26, 2024

Market Price of Glenmark Pharmaceuticals Ltd

1M

1Y

3Y

5Y

Monitoring Glenmark Pharmaceuticals Ltd share price can help you stay informed about potential market shifts and opportunities. *All values are in Rupees.

Last Ten Days Market Price

Date
leftPrice (₹)right
24 Dec 20241536.15
23 Dec 20241549.95
20 Dec 20241542.35
19 Dec 20241540
18 Dec 20241524.2
17 Dec 20241512.6
16 Dec 20241551.4
13 Dec 20241517.2
12 Dec 20241534.5
11 Dec 20241526.1

SWOT Analysis Of Glenmark Pharmaceuticals Ltd

Strength

4

S

Weakness

2

W

Opportunity

1

O

Threats

1

T

BlinkX Score for Glenmark Pharmaceuticals Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

Asset Value vs Market Value of Glenmark Pharmaceuticals Ltd

Market Value

0

Asset Value

0

* All values are in Rupees

Competitive Comparison of Market Cap

Key Valuation Metric of Glenmark Pharmaceuticals Ltd

No data available

No data available

Historical P/E Ratio of Glenmark Pharmaceuticals Ltd

No data available

* All values are in %

Historical Revenue of Glenmark Pharmaceuticals Ltd

No data available

* All values are in crore

Historical EBITDA of Glenmark Pharmaceuticals Ltd

No data available

* All values are in crore

Historical Net Profit of Glenmark Pharmaceuticals Ltd

No data available

* All values are in crore

Historical Dividend Payouts of Glenmark Pharmaceuticals Ltd

No data available

* All values are in

About Glenmark Pharmaceuticals Ltd

  • Glenmark Pharmaceuticals Ltd was incorporated in November 18th, 1977.
  • The Company is actively involved in the discovery of new molecules both NCEs (new chemical entity) and NBEs (new biological entity).
  • It is engaged in the business of development, manufacture and marketing of pharmaceutical products both formulation and active pharmaceuticals ingredients to regulated and semi-regulated markets. The company has several molecules in various stages of pre-clinical and clinical development primarily focused in the areas of Oncology, Respiratory and Dermatology.
  • Its branded generics business has a significant presence in markets across emerging economies including India.
  • The company has 14 manufacturing facilities across US, India, Argentina, Czech Republic and Switzerland.

Glenmark Pharmaceuticals Ltd News Hub

News

Glenmark Pharmaceuticals Inc. USA launches Lacosamide Oral Solution

Glenmark Pharmaceuticals Inc., USA (Glenmark) announces the launch of Lacosamide Oral Solu...

Read more

16 Dec 2024 09:06

News

Glenmark Pharma arm launches seizure drug in US

The newly launched drug is bioequivalent and therapeutically equivalent to the reference l...

Read more

16 Dec 2024 09:41

News

Glenmark Pharmaceuticals Ltd up for third straight session

Glenmark Pharmaceuticals Ltd is up for a third straight session today. The stock is quotin...

Read more

03 Dec 2024 13:06

News

Glenmark Pharma launches Travoprost Ophthalmic Solution USP

Glenmark Pharmaceuticals Inc., USA (Glenmark) announced the launch of Travoprost Ophthalmi...

Read more

27 Nov 2024 09:12

News

Glenmark Pharma arm launches Travoprost Ophthalmic Solution in U.S market

Travoprost ophthalmic is used to treat glaucoma (a condition in which increased pressure i...

Read more

27 Nov 2024 09:59

News

Glenmark Pharmaceuticals Ltd eases for fifth straight session

Glenmark Pharmaceuticals Ltd dropped for a fifth straight session today. The stock is quot...

Read more

18 Nov 2024 13:35

Product Composition

Document

Annual Reports

N/A

dropdown
download

Credit Ratings

N/A

dropdown
download

Concalls

Data not available

FAQs for Glenmark Pharmaceuticals Ltd Market Cap

What is the market cap of Glenmark Pharmaceuticals Ltd?

As of December 26, 2024, Glenmark Pharmaceuticals Ltd has a market capitalization of ₹43348.33, however, this figure is subject to change due to fluctuations in its stock price and market conditions.

What factors influence Glenmark Pharmaceuticals Ltd's market capitalization?

Glenmark Pharmaceuticals Ltd's market capitalization is influenced by factors such as its financial performance, and the company’s ability to innovate and adapt to market trends. Moreover, macroeconomic factors like economic conditions, currency fluctuations, and global automotive industry trends also affect its market capitalization.

Can market capitalization be used to predict future stock performance of Glenmark Pharmaceuticals Ltd?

Market capitalization alone is not a reliable predictor of future stock performance, as it reflects the current value of a company's equity rather than its future potential. To forecast %s's future stock performance, investors should consider additional factors such as financial health, growth prospects, industry trends, and broader economic conditions.

How often does Glenmark Pharmaceuticals Ltd's market capitalization change?

Glenmark Pharmaceuticals Ltd's market capitalization can change frequently, within a single trading day, due to fluctuations in stock price. These changes are influenced by market conditions, investor sentiment, company performance, and broader economic factors. Therefore, tracking its market capitalization requires continuous monitoring of stock price movements and related financial news.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Demat Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Demat Account
Verify your phone
+91
*By signing up you agree to our terms & conditions